SUMMARY

Post-traumatic stress disorder (PTSD) is a common mental health condition in Australia, with higher prevalence in certain populations, such as veterans and disaster survivors.

Clinicians should maintain a low threshold to assess for trauma because PTSD often presents with somatic symptoms or can be masked by comorbidities such as depression and substance use.

Trauma-focused psychotherapies (prolonged exposure, cognitive processing therapy, eye movement desensitisation and reprocessing) are the first-line treatment for PTSD. Pharmacotherapy is used as an adjunct or when psychotherapy is ineffective or unavailable.

Selective serotonin reuptake inhibitors (paroxetine, sertraline, fluoxetine) and the serotonin–noradrenaline reuptake inhibitor venlafaxine are first-line pharmacotherapies, although non-response rates are high. If antidepressant monotherapy is ineffective, adjunct therapies may be considered, including alpha-adrenergic drugs (e.g. prazosin) and select antipsychotics (e.g. quetiapine). Benzodiazepines are not recommended because they may increase the risk of developing PTSD after trauma and may impair fear extinction learning.

A validated tool such as the PTSD Checklist for DSM-5 should be used to monitor treatment response. Failure to achieve a 20 to 30% symptom reduction after 8 to 12 weeks of psychotherapy and/or pharmacotherapy should prompt review of treatment and/or referral to a psychiatrist or clinical psychologist.

3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy and neurostimulation are emerging options for treatment-resistant PTSD.

 

Introduction

Post-traumatic stress disorder (PTSD) is a debilitating, systemic condition that may occur following exposure to a traumatic event and is characterised by a complex interplay of neurobiological, cognitive and emotional dysregulation.1 Although historically conceptualised as a fear-based anxiety disorder, modern understanding recognises PTSD as a heterogeneous condition involving memory processing deficits, neurotoxicity of chronic stress and disturbances in emotional regulation, self-concept and relationships.2

PTSD often presents with somatic symptoms, such as gastrointestinal disturbance, headaches or fatigue, or with comorbidities such as depression and disorders of substance use, rather than with a clear report of trauma. The presentation of trauma-related conditions, including PTSD, may vary across populations and can be influenced by social, cultural and occupational factors.

It is important to distinguish PTSD from acute stress disorder. Acute stress disorder is characterised by trauma-related symptoms occurring within 1 month of a traumatic event. Although many individuals with acute stress disorder will go on to develop PTSD, the majority will remit with appropriate support.

Distinguishing classic PTSD from complex PTSD is increasingly relevant. Complex PTSD, formally recognised in the International Classification of Diseases 11th Revision (ICD-11),3 typically arises from prolonged, repetitive trauma (e.g. childhood abuse) and includes disturbances in self-organisation, such as severe affect dysregulation and persistent relationship difficulties. Complex PTSD is generally associated with greater functional impairment and a more chronic disease course.4 The diagnosis and management of complex PTSD may differ significantly from that of classic PTSD and is beyond the scope of this article.

 

Epidemiology and diagnosis

PTSD is the second most prevalent mental health condition in Australia, with an annual prevalence of 5.6% in the general adult population5 and higher in high-risk populations, such as veterans (17%)6 and survivors of natural disasters (25%).7

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) outlines 4 core symptom clusters of PTSD (Box 1).8 PTSD is diagnosed when symptoms from each of the core symptom clusters persist for more than 1 month following exposure to actual or threatened death, serious injury or sexual violence.

Box 1 Core symptom clusters of post-traumatic stress disorder8

Intrusion: flashbacks, nightmares and involuntary memories

Avoidance: avoiding external reminders (e.g. places, people) or internal reminders (e.g. memories, feelings)

Negative alterations in cognition and mood: shame, guilt, emotional numbing and negative beliefs about oneself or the world

Alterations in arousal and reactivity: hypervigilance, startle response and irritability


General practitioners (GPs) should be alert to subsyndromal presentations, which cause significant impairment and are a major risk factor for developing PTSD.

 

Management of comorbidities

Comorbidity is the norm rather than the exception; up to 78% of patients with PTSD have comorbid conditions, particularly major depressive disorder and disorders of substance use. Physical comorbidities, including cardiovascular disease and chronic pain, are also common due to the high allostatic (physiological) load associated with chronic stress.2 Clinical assessment of an individual with PTSD should include review of depression, substance use and physical health.

Historically, patients with disorders of substance use were required to achieve abstinence before being accepted into treatment for PTSD (sequential treatment); however, this approach is now considered outdated. Current evidence supports integrated treatment, whereby PTSD and disorders of substance use are treated concurrently (e.g. the Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure [COPE] protocol).9 Pharmacotherapies for disorders of substance use (e.g. naltrexone for alcohol, buprenorphine for opioids) should be used alongside trauma-focused therapy.10

 

Management of PTSD

The cornerstone of PTSD management is trauma-focused psychotherapy, with pharmacotherapy as adjunct or second-line therapy (Figure 1). Guidelines recommend trauma-focused psychotherapies as first-line interventions because of their superior effect sizes compared with pharmacotherapy.11

Figure 1 Assessment and treatment of post-traumatic stress disorder in primary care

Flow diagram outlining a primary care approach to assessing and treating post-traumatic stress disorder (PTSD). Patients presenting with trauma-related, mood or anxiety symptoms, or unexplained persistent somatic symptoms should be assessed for PTSD, including trauma history and comorbidities. If PTSD diagnostic criteria are met, assess complexity and risk. Patients who are high risk or have complex presentations should be referred to a psychiatrist or trauma-trained psychologist and may require more frequent review and interim pharmacotherapy. Patients who are not high risk or complex should receive first-line treatment with trauma-focused psychotherapy and, if indicated, a selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor. Treatment response should be monitored using a validated tool such as the PTSD Checklist for DSM-5 and reviewed after 8 to 12 weeks. Patients with at least a 20 to 30% improvement in symptoms should continue treatment; adjunctive pharmacotherapies may be considered for specific symptoms. If improvement is inadequate, review treatment and consider alternative first-line therapies, adjunctive therapies and/or non-GP specialist referral. Patients who do not meet the diagnostic criteria for PTSD should receive psychoeducation and ongoing monitoring.

Psychological therapies

Evidence-based trauma-focused psychotherapies include:

  • prolonged exposure: imaginal and in vivo exposure to trauma reminders to facilitate fear extinction and emotional processing
  • cognitive processing therapy: challenging of maladaptive beliefs (‘stuck points’) related to safety, trust and control
  • eye movement desensitisation and reprocessing: bilateral stimulation (e.g. eye movements) while processing traumatic memories.

Most commonly, these therapies are delivered weekly, or up to 2 to 3 times per week, with an appropriately trained clinician (e.g. a psychiatrist, psychologist or other mental health professional). In Australian primary care, access to these therapies can be financially subsidised through a Mental Health Treatment Plan and referral from a GP. However, it is important to confirm that the clinician has specific training in these therapies. Intensive or ‘massed’ protocols, in which treatment is provided daily for a fortnight, now exist and have shown promise with non-inferior outcomes and lower dropout rates,12 although they are not yet standard of care. Targeted brief psychotherapies, such as nightmare rescripting (e.g. imagery rehearsal therapy), can also be useful adjuncts.13

Pharmacotherapies

Pharmacotherapy is generally considered an adjunct to psychotherapy or a second-line treatment. However, pharmacotherapy is often necessary when psychotherapy is insufficiently effective, unavailable, refused or declined, or when symptom severity (e.g. severe depression) precludes engagement in psychotherapy. The main role of pharmacotherapy is to manage symptoms and comorbidities and support functional recovery, rather than to eliminate post-traumatic stress. Table 1 outlines the pharmacological treatment options for PTSD.

Table 1 Pharmacological treatments for post-traumatic stress disorder

Drug class Drug(s) Place in therapy Precautions, adverse effects and monitoring

Selective serotonin reuptake inhibitor (SSRI)

Paroxetine (the only SSRI that is TGA-approved for PTSD)

Sertraline

Fluoxetine

First-line pharmacotherapy

50 to 60% response rate

Common adverse effects include gastrointestinal disturbance and sexual dysfunction

Serotonin–noradrenaline reuptake inhibitor (SNRI)

Venlafaxine

First-line pharmacotherapy

Monitor blood pressure

Similar common adverse effects to SSRIs, but withdrawal symptoms are more likely with SNRIs

Alpha1-adrenergic receptor antagonist

Prazosin

Adjunct to antidepressants (particularly for sleep disturbance and hyperarousal)

Monitor for headaches and hypotension

Antipsychotic

Quetiapine

Adjunct to antidepressants (particularly for symptoms of re-experiencing and hyperarousal)

Significant metabolic adverse effects (e.g. weight gain, dyslipidaemia, increased diabetes risk)

Brexpiprazole

Adjunct to antidepressants

Monitor for extrapyramidal adverse effects, including akathisia

Psychedelic-assisted psychotherapy

MDMA

Third-line pharmacotherapy; for adults with treatment-resistant PTSD who are not likely to be re-exposed to significant trauma during treatment

Limited by cost and specialist access; must be prescribed by an appropriately trained psychiatrist (TGA Authorised Prescriber)

First clinical practice guideline published in 202514

Anticonvulsant

Topiramate

Limited evidence for PTSD-related nightmares and comorbid substance use

Monitor for weight loss and cognitive impairment

NMDA antagonist

Ketamine

Esketamine

Limited evidence

Transient hypertension and dissociation after dose

MDMA = 3,4-methylenedioxymethamphetamine; NMDA = N-methyl-D-aspartate; PTSD = post-traumatic stress disorder; TGA = Therapeutic Goods Administration

Antidepressants

Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacological treatment for PTSD. In Australia, paroxetine is the only SSRI approved for PTSD; however, sertraline, fluoxetine and the serotonin–noradrenaline reuptake inhibitor (SNRI) venlafaxine are also first-line options. The evidence suggests that antidepressants have modest efficacy in PTSD. A 2021 meta-analysis found that antidepressants were associated with a small-to-medium reduction in PTSD symptoms compared with placebo (standardised mean difference 0.28).15 Although antidepressants can alleviate symptoms, they rarely induce full remission. The usual starting doses, therapeutic dose ranges and adverse effects are similar to those for major depressive disorder. Because partial response to antidepressants is likely, it may take longer to effectively assess treatment response (8 to 12 weeks). Non-response rates to SSRIs are high (approximately 40 to 50%), particularly in combat-related PTSD compared with civilian trauma.16

Adjunctive therapies and other agents

When monotherapy with an SSRI or SNRI is insufficient, a second agent may be added, although the evidence varies. All of the following agents are used off-label in PTSD.

Alpha-adrenergic drugs

Prazosin is an alpha1-adrenergic receptor antagonist used for trauma-related nightmares and hyperarousal. Although early trials were positive, a large randomised controlled trial in veterans failed to show benefit over placebo,17 leading to conflicting guideline recommendations. However, a 2020 meta-analysis suggested that prazosin is effective for specific sleep disturbances and nightmares.18 Clonidine is an alpha2-adrenergic receptor agonist that is sometimes used as an alternative, but the evidence is substantially weaker.

Antipsychotics

Antipsychotics, specifically quetiapine and risperidone, are sometimes used as adjuncts to antidepressants for treatment-resistant PTSD. Quetiapine monotherapy has shown some efficacy in reducing re-experiencing and hyperarousal.19 Low-dose quetiapine is often prescribed as a hypnotic or anxiolytic alternative to benzodiazepines, but its metabolic adverse effects necessitate careful risk–benefit analysis, particularly with longer-term use. A 2026 meta-analysis of randomised controlled trials also supports brexpiprazole augmentation of SSRIs.20

Benzodiazepines

Benzodiazepines are frequently prescribed but are not recommended for PTSD. The evidence suggests they may increase the risk of developing PTSD if given early after trauma,21 worsen the efficacy of exposure therapy by interfering with fear extinction learning and carry risks of abuse and dependence.

Psychedelic-assisted psychotherapy

3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy became available in Australia under the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme in 2023,22 although the US Food and Drug Administration rejected approval in 2024. Unlike traditional antidepressants, MDMA acts as an empathogen, increasing oxytocin concentrations and reducing amygdala activity. This allows patients to process traumatic memories without becoming overwhelmed by fear. Phase 3 trials have shown high efficacy (up to 67% remission) in severe, treatment-resistant PTSD.23 The world’s first clinical practice guideline on MDMA-assisted psychotherapy for PTSD was released in 2025 and is endorsed by the Australian National Health and Medical Research Council.14 The guideline recommends that MDMA-assisted psychotherapy be considered only for adults with persistent moderate to severe PTSD despite an adequate trial of first-line treatments and who are unlikely to be re-exposed to significant trauma during treatment. Careful consideration is required for patients with a history of significant substance misuse, and treatment should be considered only for those without current substance misuse. Currently, the cost of this treatment and its associated therapy limits access, and it remains largely confined to highly specialised settings.

Topiramate

There is modest evidence for topiramate in the management of PTSD-related nightmares24 and PTSD with comorbid alcohol use disorder;25 however, the small size of the studies and the breadth of adverse effects require careful risk–benefit assessment.

Ketamine and esketamine

Ketamine is a noncompetitive channel blocker of N-methyl-D-aspartate (NMDA) receptors. Its S-enantiomer, esketamine, has been used for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Although some monotherapy and adjunctive studies have shown an effect, longer-term studies have not been conducted and effect sizes appear to be smaller than those observed with MDMA-assisted psychotherapy.26

Cannabis

Despite popular perception, the evidence does not support the use of medicinal cannabis, either cannabidiol (CBD) or 9-tetrahydrocannabidiol (THC), for PTSD.27 THC-containing products carry a significant risk of cannabis use disorder and exacerbation of psychotic symptoms.

Neurostimulation

For patients who do not respond to psychotherapy or pharmacotherapy, neurostimulation delivered in a specialist psychiatrist-led clinic or hospital setting may be considered. Repetitive transcranial magnetic stimulation modulates cortical excitability, typically targeting the prefrontal cortex. Systematic reviews indicate potential for reducing core PTSD and depressive symptoms; however, treatment protocols vary and long-term studies are lacking.28

Monitoring treatment response

Objective monitoring of treatment response is essential for both psychotherapy and pharmacotherapy, particularly given the modest efficacy of pharmacotherapy. Validated tools, such as the PTSD Checklist for DSM-5 (PCL-5), should be used to track symptoms over time.29 If a 20 to 30% reduction in symptoms or a significant functional benefit is not achieved after a therapeutic trial (e.g. 8 to 12 weeks), alternative treatments or referral to a non-GP specialist should be considered.

When to refer to a non-GP specialist

Referral to a psychiatrist or specialised clinical psychologist is indicated for:

  • access to first-line psychological therapy
  • diagnostic uncertainty, particularly when differentiating PTSD from complex PTSD or borderline personality disorder
  • treatment resistance, such as failure of first-line SSRI and/or community-based psychotherapy
  • high risk of patient harm (e.g. acute suicidality, severe self-harm)
  • complex comorbidities (e.g. severe substance use requiring detox, dissociation that interferes with standard therapy)
  • access to advanced or emerging therapies, such as neurostimulation or MDMA-assisted psychotherapy.
 

Preventive strategies following acute trauma

Various pharmacotherapies, including beta blockers and corticosteroids, have been trialled following acute trauma in an attempt to prevent PTSD; however, there is insufficient evidence to support the use of any pharmacological intervention for this purpose. Similarly, the effectiveness of immediate post-trauma psychological interventions, such as psychological debriefing, has not been demonstrated, and these approaches are no longer routinely recommended.11,30 Instead, the most effective intervention immediately after a traumatic event is a series of supportive strategies, generally referred to as psychological first aid. Psychological first aid aims to reduce initial distress, address basic needs, restore a sense of normalcy, promote adaptive coping and facilitate engagement with social supports.31 Close monitoring of individuals whose acute stress disorder symptoms persist for several weeks is likely to identify those who progress to PTSD and facilitate early intervention.

 

Conclusion

PTSD is a common mental health condition that often presents in primary care with somatic symptoms and comorbid mental health or substance use disorders, with or without a clear report of trauma. Primary care clinicians play a central role in early identification, coordination of psychological care, initiation of pharmacotherapy where appropriate and ongoing monitoring of treatment response. Effective management requires an integrated, patient-centred model of care that addresses comorbidities and prioritises functional recovery.

 

Key practice points

  •    Consider post-traumatic stress disorder (PTSD) in patients presenting with trauma-related, mood or anxiety symptoms, or unexplained persistent somatic symptoms. Ask about trauma history and comorbidities, including depression and substance use.
  •    Refer patients to an appropriately trained clinician for trauma-focused psychotherapy, which is the first-line treatment for PTSD. If pharmacotherapy is indicated, prescribe a selective serotonin reuptake inhibitor (e.g. paroxetine) or venlafaxine.
  •    Monitor treatment response using a validated tool such as the PTSD Checklist for DSM-5.
  •    Review and adjust treatment if response is inadequate after 8 to 12 weeks; consider an alternative first-line psychotherapy or pharmacotherapy or adjunctive therapies.
  •    Refer patients to a psychiatrist or clinical psychologist if there is diagnostic uncertainty, a high risk of harm (e.g. suicidality), complex comorbidities, an inadequate treatment response or a need to consider advanced therapies.

This article was finalised on 27 October 2026.

Conflicts of interest: Rahul Khanna has received research support from the Australian Government, Victorian Government, National Health and Medical Research Council (NHMRC), US Congressionally Directed Medical Research Program, Medical Research Future Fund (investigating two massed psychotherapies for PTSD) and Latrobe Health Services Foundation (testing a digital intervention for trauma).

Rahul Khanna and Malcolm Hopwood were investigators on a US Department of Defence–funded trial examining the use of silexan (an orally administered lavender oil preparation) as adjunctive therapy for PTSD.

Malcolm Hopwood has been on advisory boards for Lundbeck (vortioxetine and brexpiprazole), Servier (agomelatine and lurasidone), Jansen (esketamine) and NeuroCo (apps). Malcolm was a co-investigator on a trial of psychedelic-assisted therapy in PTSD. He received research support from Ramsay Health Care, the NHMRC, and the US Department of Defence. He received travel support from Johnson & Johnson to attend the 2025 Royal Australian and New Zealand College of Psychiatrists Conference.

This article is peer reviewed.

 

Australian Prescriber welcomes Feedback.

 

References

  1. Burback L, Bremault-Phillips S, Nijdam MJ, McFarlane A, Vermetten E. Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. Curr Neuropharmacol 2024;22:557–635.
  2. McFarlane AC, Lawrence-Wood E, Van Hooff M, Malhi GS, Yehuda R. The Need to Take a Staging Approach to the Biological Mechanisms of PTSD and its Treatment. Curr Psychiatry Rep 2017;19:10.
  3. World Health Organization. ICD-11: International Classification of Diseases. 11th Revision. 2022. [cited 2026 Aug 13]
  4. Sarr R, Quinton A, Spain D, Rumball F. A Systematic Review of the Assessment of ICD-11 Complex Post-Traumatic Stress Disorder (CPTSD) in Young People and Adults. Clin Psychol Psychother 2024;31:e3012.
  5. Australian Bureau of Statistics. National Study of Mental Health and Wellbeing, 2020-2022. Australian Government; 2023. [cited 2026 Aug 12]
  6. Van Hooff M, Lawrence-Wood E, Hodson S, Sadler N, Benassi H, Hansen C, et al. Mental Health Prevalence, Mental Health and Wellbeing Transition Study. The Department of Defence and the Department of Veterans’ Affairs; 2018.
  7. Patrick R, Snell T, Gunasiri H, Garad R, Meadows G, Enticott J. Prevalence and determinants of mental health related to climate change in Australia. Aust N Z J Psychiatry 2023;57:710–24.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing; 2022.
  9. Back SE, Jarnecke AM, Norman SB, Zaur AJ, Hien DA. State of the Science: Treatment of comorbid posttraumatic stress disorder and substance use disorders. J Trauma Stress 2024;37:803–13.
  10. Roberts NP, Lotzin A, Schafer I. Psychological treatment of PTSD with comorbid substance use disorder (SUD): expert recommendations of the European Society for Traumatic Stress Studies (ESTSS). Eur J Psychotraumatol 2023;14:2265773.
  11. Phelps AJ, Lethbridge R, Brennan S, Bryant RA, Burns P, Cooper JA, et al. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Aust N Z J Psychiatry 2022;56:230–47.
  12. Dell L, Sbisa AM, Forbes A, O'Donnell M, Bryant R, Hodson S, et al. Effect of massed v. standard prolonged exposure therapy on PTSD in military personnel and veterans: a non-inferiority randomised controlled trial. Psychol Med 2023;53:4192–9.
  13. Albanese M, Liotti M, Cornacchia L, Mancini F. Nightmare Rescripting: Using Imagery Techniques to Treat Sleep Disturbances in Post-traumatic Stress Disorder. Front Psychiatry 2022;13:866144.
  14. Yong ASJ, Brennan SE, Bratuskins S, Freeburn A, Arunogiri S, Bedi G, et al. Clinical Practice Guidelines for the Appropriate Use of MDMA-Assisted Psychotherapy for Post-traumatic Stress Disorder. 2025. [cited 2026 Jul 28]
  15. Hoskins MD, Bridges J, Sinnerton R, Nakamura A, Underwood JFG, Slater A, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol 2021;12:1802920.
  16. Nøhr AK, Eriksson H, Hobart M, Moltke I, Buller R, Albrechtsen A, et al. Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD. Psychiatry Res 2021;301:113964.
  17. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61:928–34.
  18. Reist C, Streja E, Tang CC, Shapiro B, Mintz J, Hollifield M. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectr 2021;26:338–44.
  19. Crapanzano C, Damiani S, Casolaro I, Amendola C. Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature. Clin Psychopharmacol Neurosci 2023;21:49–56.
  20. Kotochinsky M, Alessi MR, Vieira GH, Balogun M, Sherpa NN, Lezana AG. Efficacy and tolerability of brexpiprazole augmentation of SSRI therapy in PTSD: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res 2026;192:237–44.
  21. Campos B, Vinder V, Passos RBF, Coutinho ESF, Vieira NCP, Leal KB, et al. To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A systematic review and meta-analysis. J Psychopharmacol 2022;36:449–59.
  22. Therapeutic Goods Administration. MDMA and psilocybine hub. Department of Health, Disability and Ageing; 2024. [cited 2026 Sep 9]
  23. Wolfgang AS, Fonzo GA, Gray JC, Krystal JH, Grzenda A, Widge AS, et al. MDMA and MDMA-Assisted Therapy. Am J Psychiatry 2025;182:79–103.
  24. Geldenhuys C, van den Heuvel LL, Steyn P, Seedat S. Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. CNS Drugs 2022;36:721–37.
  25. Norman SB, Luciano MT, Panza KE, Davis BC, Lyons M, Martis B, et al. A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder. Am J Psychiatry 2025;182:452–62.
  26. Sicignano DJ, Kurschner R, Weisman N, Sedensky A, Hernandez AV, White CM. The Impact of Ketamine for Treatment of Post-Traumatic Stress Disorder: A Systematic Review With Meta-Analyses. Ann Pharmacother 2024;58:669–77.
  27. Wilson J, Dobson O, Langcake A, Mishra P, Bryant Z, Leung J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry 2026;13:304–15.
  28. Petrosino NJ, Cosmo C, Berlow YA, Zandvakili A, van 't Wout-Frank M, Philip NS. Transcranial magnetic stimulation for post-traumatic stress disorder. Ther Adv Psychopharmacol 2021;11:20451253211049921.
  29. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress 2015;28:489–98.
  30. Rose S, Bisson J, Churchill R, Wessely S. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2002:CD000560.
  31. Wang L, Norman I, Edleston V, Oyo C, Leamy M. The Effectiveness and Implementation of Psychological First Aid as a Therapeutic Intervention After Trauma: An Integrative Review. Trauma Violence Abuse 2024;25:2638–56.
 

CPD for GPs questions

  • Identify and summarise three key points relevant to your scope of practice.
  • Identify the key clinical learnings that may be incorporated into the clinical assessment, work-up and/or management plan for appropriate patients.
  • If relevant, would you change any of your management strategies for those patients identified by appropriate screening, examination and investigation.

Submit answers

 

undefined

Director of Innovation and Medical Governance, Phoenix Australia, Department of Psychiatry, The University of Melbourne

Chief Clinical Officer, SANE Australia

Psychiatrist, Psychological Trauma Recovery Service, Austin Health, Melbourne

undefined

Board Member, Phoenix Australia, Department of Psychiatry, The University of Melbourne

Ramsay Health Care Professor of Psychiatry, Professorial Psychiatry Unit, Albert Road Clinic, Melbourne